Drug firm that hiked prices by 6,000% paid shareholders £400m

Advanz Pharma and former private equity owners were fined 100m by markets watchdog

A pharmaceuticals firm that inflated thyroid drug prices by up to 6,000% over a decade paid out more than 400m to shareholders and directors during the same period.

London-based Advanz Pharma - and its former private equity owners HgCapital and Cinven - were fined a combined 100m by the Competition and Markets Authority (CMA) on Thursday.